Vaxart’s tablet influenza vaccine performs well in phase I

Vaxart has announced positive safety and immunogenicity data from phase I clinical studies with its tablet-form H1N1 seasonal influenza vaccine candidate. The announcement raises hopes for a simple, painless and user-friendly method for administering flu vaccines in the future. The San Francisco-based biotechnology company says the oral vaccine generated serum anti-haemagglutinin (anti-HA) antibody responses and influenza HA-specific T-cell responses in …

End Polio now and how Disney & the Oscars played their role–by John Hewko

John Hewko, the CEO of Rotary International, started his presentation at the World Vaccine Congress Washington this past April with a very nicely put together video about how close the world actually is to eliminating Polio as a disease (watch the video here). His presentation gave us an overview of the important work all 34,000 Rotary clubs do worldwide to …

Promising #needle-free technologies for alternative #vaccine delivery

Dr Bruce Weniger, CAPT, US Public Health Service (ret.), International Professor, Research Institute for Health Sciences, Chiang Mai University and Associate Editor of Vaccines joined us a few weeks ago at the 12th annual World Vaccine Congress in Washington DC to share his views on which needle free vaccine delivery technologies are currently out there.   Bruce talked us through …